BMC Nephrology最新文献

Background: Obinutuzumab is a novel glycoengineered type II anti-CD20 monoclonal antibody with more potent and sustained B-cell depletion than rituximab. This study aimed to evaluate the efficacy and safety of obinutuzumab monotherapy in adult patients with minimal change disease (MCD).

Methods: We conducted a retrospective study including adult MCD patients treated with obinutuzumab or glucocorticoids (GC) between January 1, 2020 and June 30, 2025. The primary outcome was complete remission (CR) of nephrotic syndrome. Secondary outcomes included relapse and adverse events.

Results: 38 patients were enrolled (16 in the obinutuzumab group, 22 in the GC group). 9 patients in the obinutuzumab group had steroid-dependent or steroid-resistant MCD, and 7 were new-onset MCD treated with obinutuzumab due to GC intolerance, contraindications, or comorbidities. In new-onset MCD, patients receiving obinutuzumab were older with higher prevalence of hypertension, BMI, and HbA1c. The CR rate was 68.8% (11/16) in the obinutuzumab group, with no significant differences in CR rate or time to remission compared with GC. Multivariate Cox regression showed that obinutuzumab treatment was not independently associated with CR. No relapses were observed in the obinutuzumab group during follow-up, whereas 27.3% of GC-treated patients relapsed.

Conclusion: This single-center retrospective study provides preliminary evidence that obinutuzumab monotherapy may induce and maintain remission in selected adult MCD patients (e.g., those with GC contraindications or intolerance). While its remission rate is comparable to conventional GC therapy in our cohort, further prospective validation is required before it can be recommended as a routine alternative to GC.

Background and hypothesis: Chronic kidney disease (CKD) affects thyroid metabolism, increasing the risk of hypothyroidism and hyperthyroidism. Dialysis further alters hormone levels through impaired synthesis, iodine imbalance, and treatment-related factors. This study aimed to evaluate the prevalence and incidence of hypothyroidism and hyperthyroidism in patients with CKD on dialysis.

Methods: We conducted a search in the Scopus and PubMed databases up to November 29, 2024. We included studies reporting prevalence or incidence data on hypothyroidism or hyperthyroidism (clinical or subclinical) in CKD patients on dialysis (hemodialysis or peritoneal dialysis). A random-effects model meta-analysis of proportions was used to calculate pooled prevalence estimates.

Results: A total of 39 studies were included, with sample sizes ranging from 40 to 8840 participants. The prevalence of hypothyroidism was 15.9% (95% CI: 13.0 to 19.0; I²: 96.2%), with 5.6% for clinical hypothyroidism and 11.2% for subclinical hypothyroidism (notably higher in peritoneal dialysis). The prevalence of hyperthyroidism was 5.1% (95% CI: 2.7 to 8.2; I²: 93.8%), with 0.9% for clinical hyperthyroidism and 3.3% for subclinical hyperthyroidism. Meta-regression analyses indicated that a longer mean duration on dialysis was associated with a lower prevalence of hypothyroidism (p = 0.008). Only one study reported the incidence of hypothyroidism (10.9%) and hyperthyroidism (4.9%), thus evidence on incidence remains scarce.

Conclusion: The prevalence of hypothyroidism and hyperthyroidism in patients with CKD on dialysis is high, although with high heterogeneity among studies. Evidence on incidence remains limited and should be interpreted as exploratory. These findings support increased clinical vigilance and consideration of early detection strategies rather than definitive screening policies.